Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Vanda Pharmaceuticals, Inc. ("Vanda" or the "Company")

. (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) The investigation focuses on whether the Company and its executives violated federal securities laws with respect to its disclosures concerning business, operational, and compliance policies. Specifically, the investigation focuses on whether Vanda misled investors regarding the efficacy of tasimelteon, one of the Company's products, by manipulating aspects of tasimelteon's primary Phase III study. The Street published an article on June 19, 2013, questioning the efficacy of Vanda's clinical trial procedure. Following this news, the Company's shares dropped $2.41 or over 22%.